S01E23 ARISS Trial: Chasing Albumin ≥3.0 in Septic Shock—Does It Help?

In this episode of PRISM Rounds, we discuss the ARISS trial: JAMA Network Open (Feb 2026), “Albumin Replacement Therapy in Septic Shock: A Randomized Clinical Trial.” We break down the bedside question: If you replace 20% albumin to maintain serum albumin ≥3.0 g/dL in septic shock, does survival improve?We walk through the study design (multicenter, open-label RCT), the key result (no significant difference in 90-day mortality), what “negative but underpowered” really means, and the practical takeaway for rounds tomorrow: this trial does not support routine albumin replacement just to chase an albumin target—though albumin appeared reasonably safe in this context. PubMed: https://pubmed.ncbi.nlm.nih.gov/41712212/ (Educational content only; not medical advice.)Tags#CriticalCare #ICU #Sepsis #SepticShock #Albumin #Fluids #Resuscitation #Vasopressors #MechanicalVentilation #EvidenceBasedMedicine #JournalClub #FOAMed #JAMANetworkOpen #IntensiveCare #PRISMRounds